EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

A Canadian Survey of Research on HIV-1 Latency—Where Are We Now and Where Are We Heading?

Ana Luiza Abdalla, Gabriel Guajardo-Contreras, Andrew J Mouland

Viruses · 2024

DOI: 10.3390/v16020229 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Viruses, 2024. Verfasst von Ana Luiza Abdalla und 2 weiteren Autor:innen. Beteiligte Einrichtung: HIV-1 RNA Trafficking Laboratory, Lady Davis Institute at the Jewish General Hospital, Montreal, QC H3T 1E2, Canada. Hauptthemen laut MEDLINE: HIV-1, HIV Infections, HIV Seropositivity. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 197 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, Department of Microbiology and Immunology, Agencia Nacional de Investigación y desarrollo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Worldwide, almost 40 million people are currently living with HIV-1. The implementation of cART inhibits HIV-1 replication and reduces viremia but fails to eliminate HIV-1 from latently infected cells. These cells are considered viral reservoirs from which HIV-1 rebounds if cART is interrupted. Several efforts have been made to identify these cells and their niches. There has been little success in diminishing the pool of latently infected cells, underscoring the urgency to continue efforts to fully understand how HIV-1 establishes and maintains a latent state. Reactivating HIV-1 expression in these cells using latency-reversing agents (LRAs) has been successful, but only in vitro. This review aims to provide a broad view of HIV-1 latency, highlighting Canadian contributions toward these aims. We will summarize the research efforts conducted in Canadian labs to understand the establishment of latently infected cells and how this informs curative strategies, by reviewing how HIV latency is established, which cells are latently infected, what methodologies have been developed to characterize them, how new compounds are discovered and evaluated as potential LRAs, and what clinical trials aim to reverse latency in people living with HIV (PLWH).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV-1HIV InfectionsHIV SeropositivityHumansVirus LatencyCD4-Positive T-LymphocytesCanadaVirus Activation

Stichwörter der Autor:innen

AIDSHIV-1LRAPLWHcARTviral latencyviral reservoirs

Autor:innen und Institutionen

  • HIV-1 RNA Trafficking Laboratory, Lady Davis Institute at the Jewish General Hospital, Montreal, QC H3T 1E2, Canada.
  • Department of Microbiology and Immunology, McGill University, Montreal, QC H3A 2B4, Canada.
  • Department of Medicine, McGill University, Montreal, QC H4A 3J1, Canada.

Förderung

  • CIHR
  • Department of Microbiology and Immunology
  • Agencia Nacional de Investigación y desarrollo
  • Canadian Institutes of Health Research

Zitieren

APA

Abdalla, A. L., Guajardo-Contreras, G., & Mouland, A. J. (2024). A Canadian Survey of Research on HIV-1 Latency—Where Are We Now and Where Are We Heading?. Viruses. https://doi.org/10.3390/v16020229

Vancouver

Abdalla AL, Guajardo-Contreras G, Mouland AJ. A Canadian Survey of Research on HIV-1 Latency—Where Are We Now and Where Are We Heading?. Viruses. 2024. doi:10.3390/v16020229

BibTeX
@article{Abdalla2024,
  author = {Abdalla, Ana Luiza and Guajardo-Contreras, Gabriel and Mouland, Andrew J},
  title = {A Canadian Survey of Research on HIV-1 Latency—Where Are We Now and Where Are We Heading?},
  journal = {Viruses},
  year = {2024},
  doi = {10.3390/v16020229}
}
Kostenlos starten →